Fundraising Fox
/Companies
Sign in

Synkrino Biotherapeutics

YC S18

San Francisco, US · 2 employees · 4 known investors

Find your way into Synkrino Biotherapeutics

Sign up to see every warm intro you have to Synkrino Biotherapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Synkrino Biotherapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Synkrino Biotherapeutics develops SATIS, an AI-based system for drug discovery. The company operates in the biotechnology sector.

Also known as SF17 Therapeutics, Inc. · SF17 Therapeutics

AI & Machine LearningBiotechDeep TechHealthtechAI-powered Drug DiscoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S18)

JBJason Barbour
Jason BarbourFounder/CEO
DODavid Ott
David OttData Scientist, Co-Founder2017–2024He brings expertise in data science and machine learning to the field.

Investors · 4

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Fundamental VenturesreportedLakeway

How we know: Y Combinator's founder network · Not right? Tell us

MicroVenturesreportedAustin

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 5

Parallel BioParallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.
Paceline BioPlay Health builds a clinical decision-support platform for healthcare providers to deliver personalized menopause and women's health care. The platform serves primary care physicians and other providers treating women navigating perimenopause and menopause.
Harmonic DiscoveryHarmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.
SFA TherapeuticsSFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
Reverie LabsReverie Labs built machine learning software for pharmaceutical companies and later developed its own drug pipeline using those ML tools. The company was acquired by Ginkgo in February 2024.

Companies working in the same space as Synkrino Biotherapeutics.

Legal entities · 1

corporate structure
SF17 Therapeutics, Inc.

Frequently asked questions

What does Synkrino Biotherapeutics do?
Synkrino Biotherapeutics develops SATIS, an AI-based system for drug discovery. The company operates in the biotechnology sector.
Who founded Synkrino Biotherapeutics?
Synkrino Biotherapeutics was founded by Jason Barbour, David Ott.
Who are Synkrino Biotherapeutics's investors?
Synkrino Biotherapeutics's investors include Blue Bear Ventures, Y Combinator, Fundamental Ventures, MicroVentures.
Where is Synkrino Biotherapeutics headquartered?
Synkrino Biotherapeutics is headquartered in San Francisco, US.